Zanubrutinib: its history, current status and ... - CLL Support
Zanubrutinib: its history, current status and ongoing research
You need to be a member of this community to see this post.
5 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Second-Generation BTK Inhibitors Hit the Treatment Bullseye With Fewer Off-Target Effects
August 16, 2020
Fewer off-target effects mean second-generation BTK inhibitors offer less...
Alterations of the immune system caused by CLL B‐cells
Abstract: Here, we review the current understanding of the underlying interplay between the...
BTK inhibitors for the treatment of CLL - the current state of play of 'brutinibs'
In just a short time, in many places, BTK inhibitors (BTKi) have largely replaced...
BRUIN Study: phase 1/2 study of Pirtobrutinib (formerly Loxo 305) in relapsed or refractory B-cell malignancies
Patients discontinue BTKi's due to resistance and intolerance. We evaluated the safety and efficacy...
Related Posts
Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL- Advances in Targeted Therapy for R/R CLL OncLive videos & transcripts by Nirav Shah MD & Nicole Lamanna MD
- Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD
- A Conversation with Dr Tam about Zanubrutinib: A Novel BTK Inhibitor
- FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
